Last updated: September 8, 2026
Fesoterodine fumarate is an oral antimuscarinic approved as Toviaz for overactive bladder with urinary urgency, urinary frequency, and urge urinary incontinence. Pfizer commercialized the product globally, but the drug has moved from branded growth therapy to mature, generic-exposed product. Its commercial decline reflects patent expiry, competition from oxybutynin, tolterodine, solifenacin, mirabegron, vibegron, and generic fesoterodine, as well as payer preference for lower-cost alternatives.
Public company filings do not consistently report Toviaz revenue as a standalone line item. Pfizer has generally included the product within broader established-products or regional pharmaceutical revenue categories. The financial trajectory therefore is best assessed through launch history, patent events, generic approvals, portfolio reporting, and the competitive position of the overactive bladder market.
What is fesoterodine fumarate and how is Toviaz used?
Fesoterodine fumarate is a prodrug that is converted to 5-hydroxymethyl tolterodine, the active metabolite also associated with tolterodine therapy. Toviaz is an extended-release tablet administered once daily.
The U.S. label includes two approved strengths:
| Product |
Strength |
Typical adult dose |
FDA status |
| Toviaz |
4 mg extended-release tablet |
4 mg once daily |
Approved |
| Toviaz |
8 mg extended-release tablet |
8 mg once daily, if needed |
Approved |
The drug is indicated for adults with overactive bladder symptoms. Dose selection depends on tolerability, response, renal function, hepatic function, and concomitant use of strong CYP3A4 inhibitors. Common adverse effects include dry mouth and constipation. Urinary retention and angioedema are important labeled risks.
Toviaz competes in a market divided between antimuscarinic drugs and beta-3 adrenergic agonists. Antimuscarinics include oxybutynin, tolterodine, solifenacin, darifenacin, trospium, and fesoterodine. Beta-3 agonists include mirabegron and vibegron.
When did fesoterodine receive FDA approval?
The FDA approved Toviaz in April 2008 for overactive bladder. Schwarz Pharma developed fesoterodine, and UCB acquired Schwarz Pharma in 2006. Pfizer obtained commercialization rights and became the principal global commercial company for Toviaz.
The principal regulatory milestones are:
| Date |
Event |
| 2006 |
UCB completed its acquisition of Schwarz Pharma |
| April 2008 |
FDA approved Toviaz in the United States |
| 2008 |
European commercialization proceeded under Pfizer and UCB arrangements |
| 2012 |
FDA approved a pediatric formulation and indication expansion for certain patients |
| 2020-2022 |
U.S. generic development and approvals accelerated |
| 2022 onward |
Generic competition began materially affecting branded economics |
The original FDA approval was based on clinical studies showing reductions in urgency urinary incontinence, urinary frequency, and micturition frequency relative to placebo. The product’s commercial positioning relied on once-daily extended release and differentiation from older immediate-release antimuscarinics.
What patents protect fesoterodine fumarate and Toviaz?
Toviaz was protected by compound, formulation, and method-of-use patents. The commercial value of the estate was concentrated in the active metabolite prodrug, extended-release delivery, and treatment of overactive bladder.
Key U.S. patent families associated with fesoterodine and Toviaz include the following:
| Patent or patent family |
General subject matter |
Commercial relevance |
| US 7,348,337 |
Fesoterodine-related pharmaceutical technology |
Core composition and pharmaceutical protection |
| US 7,384,980 |
Fesoterodine formulations and administration |
Extended-release product protection |
| US 8,778,364 |
Fesoterodine formulation or dosage technology |
Potential later-expiring formulation protection |
| US 9,278,096 |
Extended-release fesoterodine dosage forms |
Later-listed product protection |
| US 9,737,499 |
Fesoterodine-related formulation or treatment claims |
Possible secondary protection |
Patent scope and enforceability depend on the specific claims, terminal disclaimers, pediatric extensions, regulatory extensions, and Orange Book listing history. Patent numbers should be checked against the current FDA Orange Book and USPTO records before being used for litigation, licensing, or launch planning.
The earliest core protection expired around the early 2020s. Later formulation patents extended parts of the listed estate into the late 2020s, but they did not necessarily prevent all generic entry. Generic companies can challenge individual patents through Paragraph IV certifications, seek non-infringement positions, or launch after expiration of the patents they consider blocking.
What is the Orange Book status of Toviaz?
Toviaz is an FDA-listed prescription drug product with an extended-release tablet dosage form. The Orange Book identifies patents and pediatric-exclusivity information relevant to abbreviated new drug applications.
The commercial significance of Orange Book listings is narrower than the total patent estate. Only patents submitted for listing and accepted under FDA rules can trigger the statutory ANDA patent-notice framework. Manufacturing, intermediate, crystalline-form, foreign, and certain process patents may remain relevant without appearing in the Orange Book.
An Orange Book review for Toviaz should examine:
- Listed patents for the 4 mg and 8 mg strengths.
- Patent expiration dates and any pediatric extension.
- Whether each patent is product, formulation, or method-of-use related.
- ANDA certifications filed against each listed patent.
- Whether any 30-month stay was triggered.
- Whether a generic applicant obtained approval for one strength, both strengths, or only a subset of indications.
When did fesoterodine lose practical market exclusivity?
Fesoterodine lost practical U.S. exclusivity when generic manufacturers obtained approval or otherwise became able to commercialize equivalent extended-release products after the principal blocking patents expired or were resolved.
The loss of exclusivity was gradual rather than a single global event:
| Period |
Market position |
Economic effect |
| 2008-2012 |
Branded launch and formulary expansion |
Prescription growth and premium pricing |
| 2013-2016 |
Mature branded antimuscarinic |
Slower growth; pressure from solifenacin and mirabegron |
| 2017-2020 |
Late branded lifecycle |
Reimbursement pressure and declining new-patient starts |
| 2021-2023 |
Generic preparation and entry |
Reduced branded volume and price compression |
| 2024 onward |
Generic-dominated market |
Limited branded growth; value concentrated in manufacturing and supply contracts |
The relevant loss-of-exclusivity date differs by country. European market entry also depends on national patent rights, supplementary protection certificates, regulatory data protection, local reimbursement, and the timing of generic applications.
Which companies are challenging or competing with Toviaz?
Competition comes from both generic fesoterodine suppliers and branded alternatives.
Generic fesoterodine manufacturers
U.S. generic development has involved companies seeking approval for fesoterodine fumarate extended-release tablets. Publicly reported applicants and suppliers have included firms such as Lupin and Zydus, although the active commercial supplier base can change as approvals, launches, authorized distributors, and manufacturing arrangements change.
Generic competition is usually strongest in state Medicaid, Medicare Part D, hospital, and managed-care channels. Retail availability depends on wholesaler stocking, pharmacy contracts, manufacturer capacity, and reimbursement spreads.
Branded and generic alternatives
| Drug |
Class |
Competitive position |
| Oxybutynin |
Antimuscarinic |
Low-cost generic; strong historical utilization |
| Tolterodine |
Antimuscarinic |
Generic competitor with a related active metabolite |
| Solifenacin |
Antimuscarinic |
Major branded-to-generic lifecycle product |
| Trospium |
Antimuscarinic |
Generic option with different pharmacokinetic characteristics |
| Darifenacin |
Antimuscarinic |
Smaller branded and generic segment |
| Mirabegron |
Beta-3 agonist |
Branded alternative with antimuscarinic-free mechanism |
| Vibegron |
Beta-3 agonist |
Newer branded competitor with expanding formulary presence |
| Fesoterodine |
Antimuscarinic |
Once-daily extended-release option, now generic exposed |
Beta-3 agonists have changed prescribing dynamics because they offer an alternative for patients who cannot tolerate anticholinergic adverse effects. Their higher branded prices have limited complete substitution, but payer coverage and clinical preferences have reduced the strategic importance of late-life-cycle antimuscarinics.
How strong is the fesoterodine patent estate?
The estate was commercially meaningful during the branded period but is weaker as a barrier to generic entry after core patents expired.
Strengths
- Extended-release delivery created product-specific protection.
- The drug had a defined overactive bladder indication.
- Later patents could complicate a simple generic launch if they covered the exact dosage form.
- Regulatory exclusivity and pediatric provisions could delay or affect approval timing.
Weaknesses
- The active ingredient is a small molecule, so biosimilar-style complexity does not apply.
- Generic applicants can rely on the established safety and efficacy record through the ANDA pathway.
- Method-of-use claims may be addressable through labeling strategies.
- Multiple antimuscarinic alternatives limit the economic value of prolonged litigation.
- Later formulation patents may not prevent approval or commercial entry for all strengths and indications.
Patent strength should therefore be assessed claim by claim. The most important questions are whether a listed patent covers the commercial extended-release tablet, whether the claims survive validity challenges, and whether a generic can launch with a permissible carve-out.
What formulation patents protect fesoterodine?
Fesoterodine’s formulation protection centers on extended release. The formulation controls conversion and exposure over a once-daily dosing interval and distinguishes Toviaz from immediate-release antimuscarinic products.
Potentially relevant formulation features include:
- Extended-release matrix or dosage-unit design.
- Controlled release of fesoterodine fumarate.
- Tablet composition and excipient combinations.
- Dissolution characteristics.
- Dose strengths of 4 mg and 8 mg.
- Stability and manufacturing processes.
Generic products must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug. A generic applicant does not need to reproduce every manufacturing step, but it must satisfy FDA requirements for the proposed product. Process patents can remain relevant to supply-chain planning even when they do not block ANDA approval.
What method-of-use patents cover fesoterodine?
Method-of-use patents may cover treatment of overactive bladder, urinary urgency, urinary frequency, urge urinary incontinence, or patient subgroups. Their commercial effect is usually narrower than composition or formulation patents.
A generic applicant may certify that a listed method-of-use patent is not infringed, is invalid, or is not relevant to the proposed label. The applicant may also use a label carve-out that omits the patented indication if FDA determines the remaining labeling is adequate.
For Toviaz, method-of-use protection is less likely to sustain premium pricing after broad antimuscarinic competition and generic substitution. The practical barrier depends on whether the protected use is central to the reference product’s approved label and prescribing demand.
What FDA regulatory pathway applies to generic fesoterodine?
Generic fesoterodine uses the ANDA pathway under Section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must demonstrate equivalence to Toviaz rather than repeat the full clinical development program.
The principal requirements include:
- Same active ingredient.
- Same dosage form and route of administration.
- Pharmaceutical equivalence.
- Bioequivalence.
- Comparable labeling, subject to permitted carve-outs.
- Compliance with current good manufacturing practice requirements.
- Adequate manufacturing and quality controls.
Because fesoterodine is an extended-release product, dissolution testing and pharmacokinetic comparability are central to approval. Manufacturing failures, tablet-release variability, or site-inspection findings can delay approval or reduce supply reliability.
What litigation and Paragraph IV risks affect Toviaz?
The main legal risk was the possibility that generic applicants would challenge listed patents before their expiration. A Paragraph IV certification states that a listed patent is invalid, unenforceable, or not infringed. The reference-product sponsor can file patent litigation within the statutory period, potentially triggering a 30-month stay of approval.
The commercial impact depends on four variables:
- The number of generic applicants.
- The patent claims challenged.
- The timing of FDA tentative or final approval.
- The economic value of launching before competing generic applicants.
Patent litigation is less economically attractive when the product has declining branded sales and several established therapeutic substitutes. In that setting, a first generic entrant may capture meaningful volume, but the expected value of prolonged litigation is constrained by rapid price erosion after multiple entrants.
Publicly available information does not establish a single settlement date that controls the entire U.S. fesoterodine market. Generic entry should be evaluated against the specific ANDA applicant, patent certification, court docket, and product strength.
What is the financial trajectory of Toviaz and fesoterodine?
Toviaz followed a standard small-molecule lifecycle:
- Initial uptake after FDA approval.
- Prescription expansion through urology and primary-care channels.
- Competition from solifenacin and newer beta-3 agonists.
- Reimbursement pressure in a crowded antimuscarinic class.
- Generic erosion after patent expiry.
- Declining branded contribution and reduced strategic priority.
Pfizer’s public reporting limits precise product-level revenue analysis because Toviaz has not consistently been disclosed as a separate global revenue line. Pfizer reports product revenue through broader categories and geographic segments, while annual reports emphasize major products and portfolio-level performance.
The financial trajectory can be summarized as follows:
| Driver |
Branded period |
Generic period |
| Price |
Premium branded pricing |
Rapid price compression |
| Volume |
Dependent on formulary access and physician adoption |
Can rise while revenue falls |
| Gross margin |
High relative to generic products |
Reduced for branded owner |
| Marketing |
Urology and primary-care promotion |
Limited branded promotional return |
| Payer position |
Tier placement determines uptake |
Generic substitution is favored |
| Strategic value |
Lifecycle-growth asset |
Mature or non-core product |
Revenue exposure for Pfizer was meaningful during the product’s growth and mature phases but became limited after generic entry. The main financial risks were lower net price, reduced prescription share, mandatory substitution, and loss of formulary preference.
For generic manufacturers, the opportunity is different. A low-volume mature product can still generate attractive returns if:
- Manufacturing is reliable.
- The supplier enters early.
- The product has limited competition.
- The applicant secures favorable wholesaler and payer contracts.
- Regulatory compliance costs remain controlled.
How does fesoterodine compare with mirabegron and vibegron?
Fesoterodine competes on established clinical familiarity, once-daily dosing, and generic affordability. Mirabegron and vibegron compete on mechanism and tolerability, particularly for patients concerned about anticholinergic effects.
| Factor |
Fesoterodine |
Mirabegron |
Vibegron |
| Class |
Antimuscarinic |
Beta-3 agonist |
Beta-3 agonist |
| Form |
Extended-release tablet |
Extended-release tablet |
Tablet |
| Generic availability |
Yes in major markets |
Market-dependent |
More limited |
| Anticholinergic burden |
Present |
Avoided |
Avoided |
| Price position |
Low after generic entry |
Branded or higher-cost |
Branded or higher-cost |
| Main advantage |
Generic cost and established use |
Non-antimuscarinic mechanism |
Non-antimuscarinic mechanism |
| Main commercial risk |
Generic commoditization |
Payer and patent pressure |
Payer and market-access pressure |
Fesoterodine remains commercially relevant where cost controls dominate and antimuscarinic therapy is accepted. Its share is more vulnerable in markets that prioritize reduced anticholinergic burden or favor beta-3 agonists for older patients.
What generic launch scenarios exist for fesoterodine?
Three launch scenarios are commercially relevant.
Single early entrant
One approved generic supplier gains temporary share before other manufacturers enter. Pricing remains above the long-run commodity level, but the reference product loses substantial volume.
Multiple concurrent entrants
Several generic companies launch within a short period. Prices fall quickly, pharmacy substitution increases, and the branded product becomes economically marginal.
Delayed or limited entry
Patent disputes, manufacturing deficiencies, or regulatory delays restrict supply. The branded product retains residual share, particularly in plans with established Toviaz formulary placement.
The most likely long-term outcome is a generic-dominated market with low branded growth and limited pricing power. Supply interruptions can create temporary opportunities, but they do not restore durable exclusivity.
What licensing deals and ownership arrangements affect fesoterodine?
Schwarz Pharma originated fesoterodine development. UCB acquired Schwarz Pharma in 2006. Pfizer later commercialized Toviaz under arrangements involving UCB and related rights. The ownership and commercialization structure is important because the company receiving revenue, the patent holder, and the company responsible for regulatory obligations may not be identical in every jurisdiction.
The key commercial implications are:
- UCB retained historical development and intellectual-property interests.
- Pfizer carried major commercialization responsibilities.
- Regional rights and supply obligations may differ by country.
- Generic entry can affect royalties, transfer pricing, and milestone economics.
- License agreements may continue after loss of exclusivity if they cover manufacturing or territorial rights.
Public financial filings generally do not provide a complete product-level breakdown of royalty flows for fesoterodine. Any valuation of residual rights requires review of the relevant license and supply agreements.
What geographic coverage does fesoterodine have?
Fesoterodine has been marketed in the United States and multiple international markets. Geographic commercial value varies significantly because patent expiry, reimbursement, generic substitution, and regulatory approval are country-specific.
| Region |
Commercial considerations |
| United States |
Orange Book patents, ANDA approvals, Paragraph IV litigation, automatic substitution |
| European Union |
National patent rights, centralized or decentralized regulatory procedures, national reimbursement |
| Japan |
Local approval, pricing revisions, and generic substitution policies |
| Canada |
Provincial reimbursement and Canadian patent linkage |
| Emerging markets |
Lower pricing, local registration, and tender-driven procurement |
The United States remains the most legally structured market for evaluating patent and generic-entry risk. Europe is more fragmented commercially because market access and reimbursement decisions occur at the national level.
What manufacturing and intellectual-property barriers remain?
The active ingredient is not the principal barrier after generic approval. The more relevant barriers are extended-release formulation development, bioequivalence, analytical methods, process validation, regulatory inspections, and commercial supply.
Manufacturing risks include:
- Failure to match dissolution profiles.
- Variability in extended-release performance.
- API sourcing constraints.
- Site-transfer delays.
- Deficiencies identified during FDA inspection.
- Recalls caused by content uniformity or stability problems.
These barriers can protect incumbent suppliers temporarily, but they do not create durable exclusivity comparable to a valid composition-of-matter patent.
Key Takeaways
- Fesoterodine fumarate is the active pharmaceutical ingredient in Toviaz, an extended-release antimuscarinic for overactive bladder.
- FDA approval occurred in April 2008.
- The product was developed by Schwarz Pharma, acquired by UCB, and commercialized globally by Pfizer.
- Core exclusivity expired around the early 2020s, with later formulation patents creating narrower residual protection.
- Generic fesoterodine has materially reduced the branded product’s pricing power and long-term revenue potential.
- Pfizer does not consistently disclose Toviaz revenue as a standalone global financial line.
- The principal competitive threats are generic fesoterodine, generic solifenacin, generic tolterodine, oxybutynin, mirabegron, and vibegron.
- Fesoterodine’s residual commercial value is concentrated in generic supply, manufacturing reliability, regional licensing, and payer access.
- The patent estate is stronger for extended-release formulation protection than for broad long-term market exclusion.
- Beta-3 agonists are reshaping the overactive bladder market by offering alternatives to antimuscarinic therapy.
FAQs About Fesoterodine Fumarate Market and Patents
Is fesoterodine fumarate still protected by patents?
Core Toviaz protection expired around the early 2020s, while certain formulation or secondary patents may extend later. The exact barrier depends on the patent, strength, jurisdiction, and generic applicant.
Is Toviaz still sold in the United States?
Toviaz has remained an FDA-approved reference product, but commercial availability and branded market share have declined following generic entry and payer substitution.
Does fesoterodine have biosimilar risk?
No. Fesoterodine is a chemically synthesized small molecule. It faces generic-drug risk through the ANDA pathway, not biosimilar competition under the Public Health Service Act.
Which overactive bladder drug is the main competitor to fesoterodine?
The answer depends on the market. Generic solifenacin, tolterodine, and oxybutynin are direct low-cost competitors, while mirabegron and vibegron are important mechanism-based alternatives.
Can a generic manufacturer launch fesoterodine before all Toviaz patents expire?
A generic company may launch after resolving listed patents, prevailing in litigation, obtaining a court-authorized entry date, using a permissible labeling carve-out, or relying on a certification that does not trigger a blocking patent outcome.
References
- U.S. Food and Drug Administration. (2008). Toviaz (fesoterodine fumarate) prescribing information.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Toviaz.
- Pfizer Inc. (2008-2023). Annual reports and Form 10-K filings.
- U.S. Patent and Trademark Office. (n.d.). Patent Center and Patent Examination Data System.
- U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application regulations and patent certifications under the Hatch-Waxman Amendments.
- UCB S.A. (2006-2023). Annual reports and financial disclosures.
